C29|cas 363600-92-4|DC Chemicals

Cas No.:	363600-92-4
Chemical Name:	Tlr2-IN-C29
Synonyms:	C29;3-[[(2-hydroxy-3-methoxyphenyl)methylene]amino]-2-methyl-benzoic acid;ChemDiv3_012645;HMS1508O17;BCP20641;s6597;3-[[(E)-(5-methoxy-6-oxocyclohexa-2,4-dien-1-ylidene)methyl]amino]-2-methylbenzoic acid;AK687970;3-[(2-Hydroxy-3-methoxybenzylidene)amino]-2-methylbenzoic acid;3-[(2-hydroxy-3-methoxyphenyl)methy;Tlr2-IN-C29
SMILES:	O(C([H])([H])[H])C1=C([H])C([H])=C([H])C(/C(/[H])=N/C2=C([H])C([H])=C([H])C(C(=O)O[H])=C2C([H])([H])[H])=C1O[H]
Formula:	C₁₆H₁₅NO₄
M.Wt:	285.2946
Purity:	>98%
Sotrage:	2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO

Description:	C29 is a Toll-like receptor 2 (TLR2) inhibitor.
In Vitro:	C29 blunts hTLR2/1 and hTLR2/6 signaling in HEK-TLR2 Stable transfectants and THP-1 Cells. C29 blocks P3C- and P2C-induced IL-8 mRNA dose-dependently in HEK-TLR2 stable transfectants. C29 also inhibits P3C- and P2C-induced IL-1β gene expression significantly at both 1 h and 4 h following stimulation, as well as both P3C- and P2C-induced NF-κB–luciferase activity in transiently transfected HEK293T cells expressing hTLR2 and an NF-κB–sensitive luciferase reporter construct. C29 preferentially inhibits TLR2/1 signaling in primary murine macrophages. C29 blocks TLR2 bacterial agonist-induced proinflammatory gene expression in HEK-TLR2 Cells and murine macrophages. C29 inhibits ligand-induced interaction of TLR2 with MyD88 and blocks MAPK and NF-κB activation[1].
References:	[1]. Vogel S, et al. Small molecule inhibitors of tlr2 signaling. WO2016164414A1

Cat. No.	Product name	Field of application
DC70332	CU-CPD107	CU-CPD107 is a TLR8-specific small molecule with unique synergistic agonist activities in the presence of ssRNA, but inactive without the aid of ssRNA.CU-CPD107 significantly inhibited of R848-induced signaling in HEK-Blue hTLR8 cells with an IC50 of 13.7 uM.CU-CPD107 only inhibited synthesized small-molecule agonist-induced TLR8 signaling without affecting other TLRs.CU-CPD107 synergistically increased IFN-β, TNF-α, IL-1β, IL-6, and IL-8 mRNA expression levels in the presence of 5 μg/ml ssRNA40 in HEK-Blue hTLR8 cells, whereas CU-CPD107 alone did not. CU-CPD107 only activated TLR8-mediated signaling in the presence of ssRNA.CU-CPD107 showed no pure agonistic activity, addressing a major challenge that has existed for previous TLR7 and TLR8 agonists as vaccine adjuvants or antiviral drugs.
DC45281	RS 09	RS 09 is a TLR4 agonist. RS 09 promotes NF-κB nuclear translocation and induces inflammatory cytokine secretion in RAW264.7 macrophages in vitro. RS 09 acts as an adjuvant in vivo; RS 09 enhances X-15 specific antibody serum concentrations, when administered with X-15-KLH in mice.
DC28386	GSK2245035	GSK2245035 is a highly potent and selective intranasal Toll-Like receptor 7 (TLR7) agonist with preferential Type-1 interferon (IFN)-stimulating properties. GSK2245035 has pEC50s of 9.3 and 6.5 for IFNα and TFNα. GSK2245035 effectively suppresses allergen-induced Th2 cytokine production in human peripheral blood cell cultures. GSK2245035 is used for asthma.
DC10276	C29	C29 is a potential TLR2 inhibitor.